Chewy Valuation Becomes Attractive as Profitability Scales

Chewy (NYSE: CHWY) is positioning itself for a recovery as the company transitions from a pandemic-driven growth story to a sustainable, profitable business model. While the stock remains significantly below its historical highs—trading at a near 80% discount from its all-time peak—the underlying fundamentals suggest a disconnect between market price and company performance. The company has expanded its ecosystem beyond simple retail, integrating pet pharmaceuticals, telehealth services, and the establishment of physical veterinary clinics. This diversification aims to increase customer lifetime value and create new revenue streams that bolster long-term sales levels. In fiscal 2025, Chewy reported net sales of $12.6 billion, representing a 6% increase year-over-year. This growth contributed to a 125% surge in operating income. Free cash flow also showed strength, rising 24% to $562 million. Although net income fell to $223 million from $393 million the previous year, the decline is largely attributed to a one-time $241 million tax benefit that skewed 2024 results. From a valuation perspective, the stock's trailing P/E of 50 appears high compared to the S&P 500 average of 31. However, forward-looking metrics are more favorable, with a forward P/E of 16. With projected net income growth of 28% for the next fiscal year and 22% in 2027, the stock may be undervalued relative to its growth trajectory.